ITGR Integer Holdings Corp
Electromedical & Electrotherapeutic Apparatus · NYSE · SEC CIK 1114483 · Fiscal year ends 12/31
Financial factors as of 2026-10-02 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-0.3%
TTM net income YoY19.3%
TTM EPS YoY22.7%
Revenue 3-yr CAGR5.6%
Net income 3-yr CAGR8.0%
Margins
Gross margin24.6%
Operating margin8.2%
Net margin5.7%
FCF margin4.5%
EBITDA margin15.9%
Returns
ROE6.0%
ROA3.1%
ROIC (approx.)5.0%
Asset turnover0.54x
Leverage & solvency
Liabilities / assets49.1%
Debt / equity0.71x
Current ratio3.98x
Interest coverage3.87x
Cash quality & payout
Operating cash flow / net income1.70x
Accruals ratio-2.1%
Payout ratio—
Capex / revenue5.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.85B | $1.72B |
| Cost of revenue | $1.35B | $1.26B |
| Gross profit | $500.39M | $459.01M |
| R&D expense | $49.50M | $53.42M |
| SG&A expense | $211.75M | $185.20M |
| Operating income | $221.26M | $208.24M |
| Interest expense | $43.21M | $56.37M |
| Pretax income | $125.40M | $147.56M |
| Income tax | $22.57M | $26.51M |
| Net income | $102.81M | $119.90M |
| EBITDA | $351.93M | $319.27M |
| EPS (basic) | 2.96 | 3.57 |
| EPS (diluted) | 2.89 | 3.36 |
| Weighted avg. shares (diluted) | 35.59M | 35.65M |
| Balance sheet | ||
| Cash & equivalents | $17.16M | $46.54M |
| Receivables | $346.08M | $245.27M |
| Inventory | $253.74M | $247.13M |
| Current assets | $770.10M | $671.12M |
| PP&E, net | $536.43M | $465.80M |
| Goodwill | $1.11B | $1.02B |
| Intangibles | $825.43M | $778.29M |
| Total assets | $3.41B | $3.08B |
| Current liabilities | $232.04M | $227.17M |
| Short-term debt | $0 | $10.00M |
| Long-term debt | $1.19B | $980.15M |
| Total debt | $1.19B | $990.15M |
| Total liabilities | $1.66B | $1.46B |
| Shareholders' equity | $1.75B | $1.62B |
| Net debt | $1.17B | $943.61M |
| Shares outstanding | 34.35M | 33.55M |
| Cash flow statement | ||
| Operating cash flow | $196.15M | $205.21M |
| Capital expenditure | $91.03M | $105.36M |
| Free cash flow | $105.12M | $99.85M |
| Investing cash flow | -$270.73M | -$195.41M |
| Financing cash flow | $43.56M | $13.32M |
| Depreciation & amortization | $130.67M | $111.03M |
| Stock-based compensation | $23.22M | $24.77M |
| Share buybacks | $50.01M | $0 |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.